EI

251.2

-0.83%↓

SAN

81.4

+0.28%↑

SHL.DE

45.79

-0.93%↓

ARGX

548.8

-1.72%↓

PHIA

23.14

+0.74%↑

EI

251.2

-0.83%↓

SAN

81.4

+0.28%↑

SHL.DE

45.79

-0.93%↓

ARGX

548.8

-1.72%↓

PHIA

23.14

+0.74%↑

EI

251.2

-0.83%↓

SAN

81.4

+0.28%↑

SHL.DE

45.79

-0.93%↓

ARGX

548.8

-1.72%↓

PHIA

23.14

+0.74%↑

EI

251.2

-0.83%↓

SAN

81.4

+0.28%↑

SHL.DE

45.79

-0.93%↓

ARGX

548.8

-1.72%↓

PHIA

23.14

+0.74%↑

EI

251.2

-0.83%↓

SAN

81.4

+0.28%↑

SHL.DE

45.79

-0.93%↓

ARGX

548.8

-1.72%↓

PHIA

23.14

+0.74%↑

Search

Galapagos NV

Open

BrancheGesundheitswesen

26.9 -2.75

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

26.78

Max

27.68

Schlüsselkennzahlen

By Trading Economics

Einkommen

48M

-106M

Verkäufe

-9.7M

65M

KGV

Branchendurchschnitt

53.92

34.393

EPS

-2.35

Gewinnspanne

-161.972

Angestellte

558

EBITDA

-48M

Empfehlungen

By TipRanks

Empfehlungen

Sell

12-Monats-Prognose

-3.8% downside

Dividenden

By Dow Jones

Nächstes Ergebnis

22. Okt. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

55M

1.9B

Vorheriger Eröffnungskurs

29.65

Vorheriger Schlusskurs

26.9

Nachrichtenstimmung

By Acuity

50%

50%

162 / 374 Ranking in Healthcare

Galapagos NV Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Aug. 2025, 17:49 UTC

Wichtige Markttreiber

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11. Aug. 2025, 17:18 UTC

Wichtige Markttreiber

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11. Aug. 2025, 16:25 UTC

Ergebnisse

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11. Aug. 2025, 23:50 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

11. Aug. 2025, 23:42 UTC

Market Talk

Global Energy Roundup: Market Talk

11. Aug. 2025, 23:42 UTC

Market Talk

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11. Aug. 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11. Aug. 2025, 23:32 UTC

Market Talk

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11. Aug. 2025, 23:02 UTC

Market Talk

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11. Aug. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11. Aug. 2025, 20:37 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11. Aug. 2025, 20:37 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Bakkt Holdings 2Q Rev $577.9M >BKKT

11. Aug. 2025, 20:37 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11. Aug. 2025, 20:22 UTC

Ergebnisse

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11. Aug. 2025, 20:22 UTC

Ergebnisse

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11. Aug. 2025, 20:22 UTC

Ergebnisse

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11. Aug. 2025, 20:22 UTC

Ergebnisse

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11. Aug. 2025, 20:22 UTC

Ergebnisse

Exodus Movement 2Q Rev $25.8M >EXOD

11. Aug. 2025, 20:14 UTC

Market Talk

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11. Aug. 2025, 19:12 UTC

Market Talk

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11. Aug. 2025, 18:56 UTC

Market Talk

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11. Aug. 2025, 18:31 UTC

Market Talk

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11. Aug. 2025, 17:43 UTC

Market Talk

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11. Aug. 2025, 17:28 UTC

Market Talk

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11. Aug. 2025, 17:16 UTC

Market Talk

Commodity Longs Fall to 11-Month Low -- Market Talk

11. Aug. 2025, 16:42 UTC

Akquisitionen, Fusionen, Übernahmen

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11. Aug. 2025, 16:27 UTC

Akquisitionen, Fusionen, Übernahmen

BBVA Says Sabadell Offer Remains in Effect

11. Aug. 2025, 16:26 UTC

Akquisitionen, Fusionen, Übernahmen

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11. Aug. 2025, 16:25 UTC

Akquisitionen, Fusionen, Übernahmen

Banco de Sabadell Announced TSB Sale on July 1

11. Aug. 2025, 16:25 UTC

Akquisitionen, Fusionen, Übernahmen

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Peer-Vergleich

Kursveränderung

Galapagos NV Prognose

Kursziel

By TipRanks

-3.8% Nachteil

12-Monats-Prognose

Durchschnitt 26.3 EUR  -3.8%

Hoch 37 EUR

Tief 19 EUR

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Galapagos NV – Dist angeboten haben.

Rating-Konsens

By TipRanks

Sell

5 ratings

1

Buy

1

Halten

3

Sell

Stimmung

By Acuity

162 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.